Delving into the Latest Updates on Cybin IRL Ltd. with Synapse

A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND)

This is a long- term extension of the double-blind trial, APPROACH (CYB003-002). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.

开始日期2025-02-23

申办/合作机构

Cybin IRL Ltd.

[+1]

NCT06564818 / Not yet recruiting临床3期

A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.

开始日期2024-11-01

申办/合作机构

Cybin IRL Ltd.

[+1]

NCT06051721 / Recruiting临床2期

A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants with Generalized Anxiety Disorder (GAD)

The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.

开始日期2024-05-10

申办/合作机构

Cybin IRL Ltd.

[+1]

100 项与 Cybin IRL Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Cybin IRL Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Cybin IRL Ltd. 相关的文献（医药）

2024-04-25·Journal of Medicinal Chemistry

Synthesis and Structure–Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT₂ Receptor Agonist

Article

作者: Palfreyman, Michael G ; Hartsel, Joshua A ; Tyagi, Richa ; Canal, Clinton E ; Avery, Ken ; Reichelt, Amy C ; Pathare, Pradip ; Morgan, Michael E ; Mueller, Tina A ; Nivorozhkin, Alex ; Stang, Erik ; Varty, Geoffrey B

Structure-activity studies of 4-substituted-2,5-dimethoxyphenethylamines led to the discovery of 2,5-dimethoxy-4-thiotrifluoromethylphenethylamines, including CYB210010, a potent and long-acting serotonin 5-HT₂ receptor agonist. CYB210010 exhibited high agonist potency at 5-HT_2A and 5-HT_2C receptors, modest selectivity over 5-HT_2B, 5-HT_1A, 5-HT₆, and adrenergic α_2A receptors, and lacked activity at monoamine transporters and over 70 other proteins. CYB210010 (0.1-3 mg/kg) elicited a head-twitch response (HTR) and could be administered subchronically at threshold doses without behavioral tolerance. CYB210010 was orally bioavailable in three species, readily and preferentially crossed into the CNS, engaged frontal cortex 5-HT_2A receptors, and increased the expression of genes involved in neuroplasticity in the frontal cortex. CYB210010 represents a new tool molecule for investigating the therapeutic potential of 5-HT₂ receptor activation. In addition, several other compounds with high 5-HT_2A receptor potency, yet with little or no HTR activity, were discovered, providing the groundwork for the development of nonpsychedelic 5-HT_2A receptor ligands.

100 项与 Cybin IRL Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Cybin IRL Ltd. 相关的转化医学

登录后查看更多信息